We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




New Technology Enables Fast Plasma Collection from Small Blood Samples

By LabMedica International staff writers
Posted on 05 May 2014
A "lab-on-a-card" collection technology now enables rapid generation of plasma from a single finger-prick blood sample, at high quality suitable for applications such as LC-MS/MS analysis.

Shimadzu Scientific Instruments (SSI; Columbia, MD, USA), subsidiary of Shimadzu Corporation (Kyoto, Japan), has introduced Noviplex Cards, a next-generation sample collection tool for accelerated blood plasma collection and analysis. More...
The cards allow for rapid collection of a volumetric sample of plasma from an unmeasured small amount of whole blood within minutes. They are ideal for uses such as LC-MS/MS analysis. Noviplex also provides exceptional reproducibility independent of hematocrit, 99% removal of red blood cells, and rapid sample preparation for MS-based analysis while maintaining assay reproducibility and selectivity.

Noviplex Cards simplify blood collection by eliminating the need for phlebotomy, syringes, and glass collection tubes. Plasma can be generated from specimen volumes ranging from 20–75 µL of whole blood. The technology offers a single-step, solid-phase method for sample preparation and analyte extraction. It accelerates processes by eliminating refrigeration, centrifugation, solvent extraction, and evaporation.

Shimadzu partnered with Novilytic Laboratories (Novilytic; North Webster, IN, USA) to offer the Noviplex Cards. “Next-generation Novilytic Laboratory advances in sample collection and preparation vastly accelerate disease marker analysis and enable a paradigm change in clinical chemistry, wellness monitoring, and medicine,” said Fred Regnier, PhD, professor emeritus, John H. Law distinguished professor of Chemistry, Purdue University, and a co-founder of Novilytic. “Noviplex technology enables lab-free sample preparation, and the convenient ‘lab-on-a-card’ format rapidly generates plasma for LC-MS/MS analysis,” said Scott Kuzdzal, PhD, life science business unit manager at SSI; “This will greatly simplify collection and processing in medical clinics, labs, and hospitals.”

Related Links:

Shimadzu Scientific Instruments
Noviplex Cards
Novilytic Laboratories



New
Gold Member
Aspiration System
VACUSAFE
New
Gold Member
Neonatal Heel Incision Device
Tenderfoot
New
Rapid Sepsis Test
SeptiCyte RAPID
New
Benchtop Thermomixer
Biometra TS1 ThermoShaker
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image

Urine-Based Multi-Cancer Screening Test Receives FDA Breakthrough Device Designation

Early detection across multiple cancers remains a major unmet need in population screening. Non-invasive approaches that can be delivered at scale may broaden access and shift diagnoses to earlier stages.... Read more

Molecular Diagnostics

view channel
Image: The new approach focuses on CpG DNA methylation, a chemical modification of cytosine and guanine bases, using tumor samples to develop a computational model that distinguishes among 21 cancer types (photo credet: 123RF)

Machine Learning Model Uses DNA Methylation to Predict Tumor Origin in Cancers of Unknown Primary

Cancers of unknown primary (CUP) are metastatic malignancies in which the primary site cannot be identified, complicating treatment selection. Many patients consequently receive broad, nonspecific chemotherapy... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.